Design Therapeutics Inc (DSGN) - Business Payback Period

Symbol and logo of brand Design Corp (DSGN)

Design Therapeutics (DSGN) relies on an innovative US-based foundation to combat muscle pathologies. The project's success depends on confirming the efficacy of small molecules, while the P/E ratio on the GURU.Markets platform, where share price quotes are displayed on a chart, stands at -9.20. Risks are associated with international patenting and logistical complexities in raw material procurement amid global instability.

DSGN Design Therapeutics Inc Price to Earnings Ratio (07/04/2022 - 11/12/2026)

Analytical breakdowns for Design Pharma (DSGN)

- market value and analyst target forecast:
Market Chart designtx.com|DSGN - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Design Therapeutics, Inc.|DSGN - Enterprise Value
- book capitalization data:
Book Value of One Share Design Therapeutics|DSGN - Company Book Value|Capitalization to Book Value Ratio designtx.com|DSGN - Cumulative Company Assets
- debt and solvency information:
All Debt to Shareholders' Equity Ratio Design Therapeutics|DSGN - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Design Corp|DSGN - Company Aggregate Debts|Debt to Net Assets Ratio Design Therapeutics, Inc.|DSGN - Company Long-Term Debts|Short-Term Debt Design Therapeutics|Intermediate Coverage Ratio designtx.com
- earnings and multiples data:
DSGN - Net Profit|Projected Future Earnings Design Therapeutics|DSGN - Price to Earnings Ratio|Price to Expected Earnings Ratio Design Therapeutics Inc|DSGN - PEG Multiple|Company Value to EBITDA Design Therapeutics, Inc.|DSGN - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Design Therapeutics|DSGN - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months designtx.com|DSGN - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Design Therapeutics
Summary company analysis:designtx.com - DSGN
Flagship merchandise of Design Therapeutics Inc

Long-term investing requires strict volatility monitoring to minimize capital loss risks. For Design Therapeutics (DSGN), this is critical due to the valuation's dependence on the success of the GeneTAC platform and Friedreich's ataxia therapy. By analyzing the company's target P/E, an investor assesses the ratio of market price to net income to determine the premium paid for future growth. This indicator allows for the precise synchronization of the current quote with the actual fundamental value of the biotech business.

Key competitors

Tempus AI Inc (TEM) - Business Payback Period|P/E Multiple QGEN|Business Payback Period Ionis Pharmaceuticals, Inc.|P/E Multiple RGEN (Repligen Corp.)|Market Cap to Net Income Ratio Avidity Corp|CRSP - Price to Earnings Ratio|WGS (genedx.com) - Price to Earnings Multiple|RARE (Ultragenyx) - Price to Earnings Ratio|Beam Therapeutics Inc - Company Value to Net Income|Price to Earnings Ratio SRPT|TWST (Twist Bioscience Corp) - Market Price to Net Income Ratio|P/E Multiple TXG|NTLA (intelliatx.com) - Company Value to Net Income|P/E Multiple STOK (Stoke Therapeutics, Inc.)|BioLife Solutions Inc (BLFS) - Market Cap to Earnings|WVE - Price to Earnings Ratio|Company Value to Net Income MAZE (Maze Therapeutics Corp)|SION: P/E Multiple|primemedicine.com (PRME) - P/E Multiple|Price to Earnings Ratio Taysha Gene Therapies, Inc.|uniQure NV - Market Cap to Net Income|P/E Multiple MGTX|RGNX - Market Cap to Earnings|Solid Biosciences Inc. - Price to Earnings Ratio|P/E Multiple ocugen.com OCGN|PACB: Price to Earnings Ratio|Benitec Biopharma Inc - Market Price to Net Income Ratio|RCKT: P/E Multiple|FDMT - Business Payback Period|LXEO (Lexeo Therapeutics Inc.) - P/E Multiple|Price to Earnings Ratio Korro Bio, Inc (KRRO)|Price to Earnings Ratio Editas Medicine (EDIT)|Business Payback Period Silence Therapeutics PLC|P/E Multiple PRQR (ProQR Therapeutics)|CDXS: Price to Earnings Multiple|SGMO - Price to Earnings Ratio|Business Payback Period Nautilus Biotechnology NAUT|MGX: P/E Multiple|Market Cap to Net Income Ratio precisionbiosciences.com DTIL|Price to Earnings Ratio Generation Bio Co|Price to Earnings Multiple BOLD (Boundless Bio Inc)|P/E Multiple XCUR|imunon.com - Price to Earnings Multiple|Price to Earnings Ratio Phio Pharmaceuticals Corp. PHIO|MBIO: Price to Earnings Multiple|TransCode - P/E Multiple|BNGO - P/E Multiple|APDN: P/E Multiple|Price to Earnings Multiple BLUE|IPA (ImmunoPrecise Antibodies Ltd) - P/E Multiple|Market Cap to Earnings Omega Therapeutics Inc OMGA|Price to Earnings Ratio Singular Genomics Systems Inc (OMIC)|Business Payback Period Regulus|P/E Multiple SYRS (Syros Pharmaceuticals)|Business Payback Period telesisbio.com (TBIO)|TRACON Pharmaceuticals, Inc. - P/E Multiple|Market Cap to Net Income Ratio Unity Biotechnology Inc. (UBX)